Loading patent…
OwnerCarlos Lopez-Otin, Jose Maria Perez Freije +4inventors
InventorsCarlos Lopez-Otin, Jose Maria Perez Freije, Santiago Cal Miguel, Jose Manuel Lopez Garcia, Albert Bernard Bianchi, Pamela Trail
Estimating the term…
Compositions and methods are provided for identifying and designing modulators of integrin-mediated cell-cell interactions through altering the interaction of ADAM 23 with αvβ3 integrin. Compositions and methods are also provided for modulating integrin-mediated cell-cell interactions such as those involved in angiogenesis, induction of active metalloproteinases, tumor progression and neural tissue growth.
An isolated nucleic acid sequence encoding ADAM 23.
A method for identifying modulators of integrin-mediated cell-cell interactions comprising contacting a host cell expressing ADAM 23 or a peptide thereof with a test agent and determining the ability of the test agent to alter interaction of ADAM 23 or the peptide with αvβ3 integrin wherein a test agent which alters the interaction of ADAM 23 or the peptide with αvβ3 integrin is identified as a modulator of integrin-mediated cell-cell interactions.
A synthetic peptide comprising SEQ ID NO:1 or a variant thereof which modulates the interaction of ADAM 23 with αvβ3 integrin.
A method of modulating integrin-mediated cell-cell interactions comprising contacting cells with a modulator which alters the interaction of ADAM 23 with αvβ3 integrin.
A method for inhibiting tumor progression in a patient comprising administering to the patient a modulator of the interaction of ADAM 23 with αvβ3 integrin.
A method for inducing growth of neural tissue comprising contacting neural tissue with a modulator of the interaction of ADAM 23 with αvβ3 integrin.
A composition which alters integrin-mediated cell-cell interactions comprising a modulator of the interaction of ADAM 23 with αvβ3 integrin.
A pharmaceutical composition for altering integrin-mediated cell-cell interactions comprising an effective amount of a modulator of the interaction of ADAM 23 with αvβ3 integrin and a pharmaceutically acceptable vehicle.
A composition which inhibits tumor progression comprising a modulator of the interaction of ADAM with αvβ3 integrin, wherein said modulator inhibits or antagonizes the interaction of ADAM with αvβ3 integrin.
A composition which induces growth of neural tissue comprising a modulator of the interaction of ADAM with αvβ3 integrin, wherein said modulator activates or agonizes the interaction of ADAM with αvβ3 integrin.
Dependencies are inferred from the claim text.